Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Core Insights - MiNK Therapeutics, Inc. is experiencing a significant increase in stock price, with INKT stock rising 471.3% to $44.16 [7] - The company is focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, with promising clinical results reported [2] Clinical Developments - A landmark case published in Nature's Oncogene reported a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer after receiving a single infusion of agenT-797 combined with Bristol-Myers Squibb's Opdivo [2][3] - The patient showed no evidence of disease over two years, with donor iNKT cells detectable for up to six months post-infusion, and the treatment was well-tolerated without severe side effects [4] - Data from a Phase 2 trial in 2L gastric cancer presented at the 2025 AACR Immuno-Oncology meeting indicated immune activation and early signs of tumor control in patients previously resistant to checkpoint inhibitors, with some patients surviving beyond 12 months [5] - A separate peer-reviewed case report noted a patient with metastatic gastric cancer achieving a 42% tumor reduction and over nine months of progression-free survival following a single infusion of agenT-797 combined with nivolumab [6] Market Activity - The trading volume for INKT stock reached 20.2 million, significantly higher than the average volume of 7.5 million [1]